Cardiac Amyloidosis Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Cardiac Amyloidosis Market is segmented By Product Type (Light Chain Amyloidosis, Transthyretin Amyloidosis), By Treatment (Chemotherapy, Surgery, Sup....
Cardiac Amyloidosis Market Size
Market Size in USD
CAGR6.2%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 6.2% |
| Market Concentration | High |
| Major Players | Pfizer, Alnylam Pharmaceuticals, Alexion Pharmaceuticals/Eidos Therapeutics, Ionis Pharmaceuticals, AstraZeneca |
please let us know !
Cardiac Amyloidosis Market Analysis
The Global Cardiac Amyloidosis Market is estimated to be valued at USD 6.12 Bn in 2024 and is expected to reach USD 11.45 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
The Cardiac Amyloidosis Market is expected to witness positive growth over the forecast period due to increasing prevalence of AL amyloidosis and familial amyloid polyneuropathy which is primarily driving the market. With no approved therapies for ATTR amyloidosis sub-type, the industry is also likely to grow due to promising late-stage pipeline drugs for cardiomyopathy associated with hereditary ATTR amyloidosis. Increased research funding and investments from key players to develop innovative treatment options are further expected to propel the Cardiac Amyloidosis Market during the forecast period.